GlobeNewswire·Nov 10, 2026, 3:50 PM ET

Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion

Exicure, Inc. & its subsidiary GPCR Therapeutics USA Inc. entered an agreement on November 4, 2026, to sell the GPC-100 (burixafor) program assets to GPCRT Inc. of South Korea.
The total cash purchase price is KRW 6.5 billion (approximately US$4.8 million).
The assets include rights under the January 19, 2025 License & Collaboration Agreement with GPCR Therapeutics, Inc., along with related contracts, intellectual property, clinical data, materials, & equipment.
GPC-100 is being evaluated for stem cell mobilization in multiple myeloma patients using propranolol, following a completed Phase 2 trial in January 2026.
Payment terms include a prior credit of KRW 500 million, KRW 2.0 billion due by November 16, 2026, & the remaining KRW 4.0 billion payable at closing.
GPCRT will assume all future obligations, milestone payments, royalties, & program costs incurred on or after September 1, 2026.
Exicure & GPCR USA will retain all liabilities incurred before September 1, 2026.
GPCR USA will remain a wholly owned subsidiary of Exicure post-closing.
The transaction is subject to customary conditions, including stockholder approval, third-party consents, & a waiver from GPCR Therapeutics, Inc.
The sale is part of Exicure's strategy to maximize stockholder value & strengthen its financial position following its 2025 restructuring.

Company: Exicure, Inc.
Keywords: Nasdaq:XCUR, Exicure, Inc., Exicure, GPC-100, burixafor, GPCRT, stem cell mobilization, multiple myeloma, sale